Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Sarizotan in Parkinson Patients With L-dopa-induced Dyskinesia

This study has been completed.
Sponsor:
Information provided by:
EMD Serono
ClinicalTrials.gov Identifier:
NCT00314288
First received: April 12, 2006
Last updated: October 22, 2013
Last verified: October 2013
  Purpose

The primary purpose of the study is to investigate the anti-dyskinetic effect of several doses of sarizotan in Parkinson patients in order to generate information on the dose-response relationship (dose-finding).


Condition Intervention Phase
Parkinson's Disease
Dyskinesia
Drug: Sarizotan HCl
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Multicenter, Multinational, Randomised, Double-blind, Placebo-controlled, Parallel-group, Dose-finding Study to Investigate the Anti-dyskinetic Efficacy and Safety of Sarizotan in Parkinson Patients With L-dopa-induced Dyskinesia

Resource links provided by NLM:


Further study details as provided by EMD Serono:

Estimated Enrollment: 360
Study Start Date: July 2002
Estimated Study Completion Date: July 2003
  Eligibility

Ages Eligible for Study:   30 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or Female
  • The subject is an out-patient
  • Age 30 years or above
  • Dyskinesias present during more than 25% of the waking day
  • Dyskinesias at least moderately disabling
  • Written informed consent

Exclusion Criteria:

  • Pregnancy and/or lactation
  • Participation in another study within the last 30 days
  • Dementia or other psychiatric illness that prevents provision of informed consent
  • History of allergic disorders such as asthma
  • Known hypersensitivity to the study treatment(s)
  • Known hypersensitivity to ACTH
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00314288

  Show 51 Study Locations
Sponsors and Collaborators
EMD Serono
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00314288     History of Changes
Other Study ID Numbers: EMR 62225-006
Study First Received: April 12, 2006
Last Updated: October 22, 2013
Health Authority: United States: Food and Drug Administration
Germany: Federal Institute for Drugs and Medical Devices
Belgium: Directoraat Generaal Geneesmiddelen
Bulgaria: Bulgarian Drug Agency
Canada: Health Canada
France: Agence Française de Sécurité Sanitaire des Produits de Santé
Portugal: Instituto Nacional da Farmácia e do Medicamento
Romania: National Medicines Agency
South Africa: Medicines Control Council
United Kingdom: Medicines and Healthcare Products Regulatory Agency
Hungary: National Institute of Pharmacy

Keywords provided by EMD Serono:
Parkinson's Disease
Dyskinesia
L-dopa-induced dyskinesia

Additional relevant MeSH terms:
Dyskinesias
Parkinson Disease
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Movement Disorders
Nervous System Diseases
Neurodegenerative Diseases
Neurologic Manifestations
Parkinsonian Disorders
Signs and Symptoms

ClinicalTrials.gov processed this record on November 25, 2014